HLA-E binding
US7410767B1 · kind B1 · utility
3Cited by
0References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 1998 |
| Grant date | Aug 12, 2008 |
| Priority date | — |
| Expiry date | Dec 4, 2018 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/7056
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.